Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis
What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.
Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.
Sex ratio of multiple sclerosis in Canada: a longitudinal study.
Confronting the diagnosis of multiple sclerosis: a qualitative study of patient experiences.
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve
Painful Tonic Spasm in Neuromyelitis Optica: Incidence, Diagnostic Utility, and Clinical Characteristics.
In vitro screening of NADPH oxidase inhibitors and in vivo effects of L-leucinethiol on experimental autoimmune encephalomyelitis-induced mice.
The "liberation procedure" for multiple sclerosis: sacrificing science at the altar of consumer demand.
Recommendations for diagnosis and management of multiple sclerosis.
Gray matter is targeted in first-attack multiple sclerosis.
Fatal Neuroinflammation in a Case of Multiple Sclerosis with Anti-Natalizumab Antibodies.
Development of a Computer-aided Diagnostic System for Detecting Multiple Sclerosis Using Magnetic Resonance Images.
Client-centred therapy in multiple sclerosis: More intensive diagnostic evaluation and less intensive treatment.
Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis.
T cell-intrinsic ASC critically promotes TH17-mediated experimental autoimmune encephalomyelitis.
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.
[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis.]
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
Pages
« first
‹ previous
…
170
171
172
173
174
175
176
177
178
…
next ›
last »